Andrew B Smitherman1,2, Chelsea Anderson3, Jennifer L Lund2,3, Jeannette T Bensen2,3, Donald L Rosenstein2,4, Hazel B Nichols2,3. 1. 1 The Division of Pediatric Hematology/Oncology, University of North Carolina , Chapel Hill, North Carolina. 2. 2 The Lineberger Comprehensive Cancer Center, University of North Carolina , Chapel Hill, North Carolina. 3. 3 The Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina , Chapel Hill, North Carolina. 4. 4 The Department of Psychiatry, University of North Carolina , Chapel Hill, North Carolina.
Abstract
PURPOSE: Cancer survivors are at increased risk for the early development of age-related chronic medical conditions compared with peers without a history of cancer; however, little is known regarding the burden of these conditions among survivors of adolescent and young adult (AYA) cancers. In response, we sought to determine the prevalence of specific comorbidities and frailty among AYAs (15-39 years old at diagnosis) enrolled in a cancer survivorship cohort. METHODS: Using a cross-sectional survey of a tertiary medical center-based cancer survivorship cohort, we determined the prevalence of specific comorbidities and frailty using the survey-based FRAIL assessment. In separate models adjusting for age, we estimated prevalence ratios (PRs) for the associations between patient characteristics and (1) any comorbidity and (2) frailty or prefrailty using log-binomial models. RESULTS: We identified 271 AYA cancer survivors, most of whom were 30-39 years old at survey (57%). A majority of survivors (n = 163, 60%) reported having at least one comorbidity with the most common being depression (28%), anxiety (27%), asthma (17%), high cholesterol (15%), and hypertension (15%). Of the 184 AYA survivors at least 1 year from cancer diagnosis, 19 (10%) were classified as frail and 39 (21%) as prefrail. Survivors who were smokers (PR 2.0, 95% confidence interval [CI]: 1.16-3.56); obese (PR 1.7, 95% CI: 1.10-2.55); uninsured (PR 2.7, 95% CI: 1.63-4.59); or who reported comorbid depression or anxiety (PR 2.4, 95% CI: 1.51-3.67) were more likely to be frail or prefrail. CONCLUSIONS: The prevalence of frailty and comorbidities is high among AYA cancer survivors suggestive of accelerated aging.
PURPOSE:Cancer survivors are at increased risk for the early development of age-related chronic medical conditions compared with peers without a history of cancer; however, little is known regarding the burden of these conditions among survivors of adolescent and young adult (AYA) cancers. In response, we sought to determine the prevalence of specific comorbidities and frailty among AYAs (15-39 years old at diagnosis) enrolled in a cancer survivorship cohort. METHODS: Using a cross-sectional survey of a tertiary medical center-based cancer survivorship cohort, we determined the prevalence of specific comorbidities and frailty using the survey-based FRAIL assessment. In separate models adjusting for age, we estimated prevalence ratios (PRs) for the associations between patient characteristics and (1) any comorbidity and (2) frailty or prefrailty using log-binomial models. RESULTS: We identified 271 AYA cancer survivors, most of whom were 30-39 years old at survey (57%). A majority of survivors (n = 163, 60%) reported having at least one comorbidity with the most common being depression (28%), anxiety (27%), asthma (17%), high cholesterol (15%), and hypertension (15%). Of the 184 AYA survivors at least 1 year from cancer diagnosis, 19 (10%) were classified as frail and 39 (21%) as prefrail. Survivors who were smokers (PR 2.0, 95% confidence interval [CI]: 1.16-3.56); obese (PR 1.7, 95% CI: 1.10-2.55); uninsured (PR 2.7, 95% CI: 1.63-4.59); or who reported comorbid depression or anxiety (PR 2.4, 95% CI: 1.51-3.67) were more likely to be frail or prefrail. CONCLUSIONS: The prevalence of frailty and comorbidities is high among AYA cancer survivors suggestive of accelerated aging.
Authors: Maud M Geenen; Mathilde C Cardous-Ubbink; Leontien C M Kremer; Cor van den Bos; Helena J H van der Pal; Richard C Heinen; Monique W M Jaspers; Caro C E Koning; Foppe Oldenburger; Nelia E Langeveld; Augustinus A M Hart; Piet J M Bakker; Huib N Caron; Flora E van Leeuwen Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Kirsten K Ness; Kevin R Krull; Kendra E Jones; Daniel A Mulrooney; Gregory T Armstrong; Daniel M Green; Wassim Chemaitilly; Webb A Smith; Carmen L Wilson; Charles A Sklar; Kyla Shelton; Deo Kumar Srivastava; Sabeen Ali; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-18 Impact factor: 44.544
Authors: Catherine C Cowie; Keith F Rust; Earl S Ford; Mark S Eberhardt; Danita D Byrd-Holt; Chaoyang Li; Desmond E Williams; Edward W Gregg; Kathleen E Bainbridge; Sharon H Saydah; Linda S Geiss Journal: Diabetes Care Date: 2008-11-18 Impact factor: 17.152
Authors: John M Salsman; Suzanne C Danhauer; Justin B Moore; Mollie R Canzona; David E Victorson; Bradley J Zebrack; Bryce B Reeve Journal: Cancer Date: 2020-09-10 Impact factor: 6.860
Authors: Sarah Pranikoff; Vanessa L Ayer Miller; Hillary Heiling; Allison M Deal; Carmina G Valle; Grant R Williams; Hyman B Muss; Hazel B Nichols; Andrew B Smitherman Journal: Cancer Date: 2022-03-23 Impact factor: 6.921
Authors: Winnie M C van den Boogaard; Marry M van den Heuvel-Eibrink; Jan H J Hoeijmakers; Wilbert P Vermeij Journal: Annu Rev Cancer Biol Date: 2020-12-02
Authors: Ibrahim Y Abdelgawad; Karim T Sadak; Diana W Lone; Mohamed S Dabour; Laura J Niedernhofer; Beshay N Zordoky Journal: Pharmacol Ther Date: 2020-12-01 Impact factor: 12.310
Authors: Ursela Christopherson; Stephanie J Wells; Nathan Parker; Elizabeth J Lyons; Michael D Swartz; Anna Blozinski; Karen Basen-Engquist; Susan Peterson; Maria C Swartz Journal: J Cancer Surviv Date: 2021-06-04 Impact factor: 4.062
Authors: Andrew B Smitherman; William A Wood; Natalia Mitin; Vanessa L Ayer Miller; Allison M Deal; Ian J Davis; Julie Blatt; Stuart H Gold; Hyman B Muss Journal: Cancer Date: 2020-08-24 Impact factor: 6.860
Authors: Chun Chao; Smita Bhatia; Lanfang Xu; Kimberly L Cannavale; F Lennie Wong; Po-Yin Samuel Huang; Robert Cooper; Saro H Armenian Journal: J Clin Oncol Date: 2020-07-16 Impact factor: 44.544